New therapies for neuromyelitis optica spectrum disorder

This rapid review describes this rare condition, and the evidence base for its treatment, including four randomised controlled trials testing the efficacy of eculizumab, satralizumab, and inebilizumab.

Source:

The Lancet Neurology